Future Medicinal Chemistry

Top Research Topics at Future Medicinal Chemistry?

The journal focuses on Pharmacology, Drug discovery, Computational biology, Biochemistry and Cancer research. The work on Pharmacology tackled in Future Medicinal Chemistry brings together disciplines like Receptor, Disease and In vivo. Future Medicinal Chemistry addresses concerns in Drug discovery which are intertwined with other disciplines, such as Combinatorial chemistry and Nanotechnology.

The study on Computational biology presented is investigated in conjunction with research in Bioinformatics. More specifically, the research on Biochemistry in it is related to Enzyme. The studies tackled, which mainly focus on Cancer research, apply to Cancer as well.

• Pharmacology (20.76%)
• Drug discovery (17.64%)
• Computational biology (12.71%)

What are the most cited papers published in the journal?

• Inhibition of Ras for cancer treatment: the search continues (310 citations)
• Strategies for discovering and derisking covalent, irreversible enzyme inhibitors (283 citations)
• Macrocycles in new drug discovery (276 citations)

Research areas of the most cited articles at Future Medicinal Chemistry:

The most cited papers mainly deal with areas of study such as Pharmacology, Drug discovery, Biochemistry, Computational biology and Drug. While Pharmacology is the key highlight in the journal publications, thet also covered some subjects on Cancer research and Immunology. The most cited publications focus on Drug discovery but the discussions also offer insight into other areas such as Nanotechnology and Medicinal chemistry.

What topics the last edition of the journal is best known for?

• Enzyme
• Gene
• Internal medicine

The previous edition focused in particular on these issues:

The journal focuses largely on the fields of Computational biology, Pharmacology, Cancer research, Biochemistry and Cancer. The studies in Computational biology featured incorporate elements of Virtual screening, Molecular dynamics, Identification (biology), Small molecule and Drug discovery. Virtual screening research discussed connects with the study of Protease.

Topics in Pharmacology explored in Future Medicinal Chemistry were investigated in conjunction with research in In vitro and In vivo. Most of the works presented in it deals with In vitro but it intersects with the subject of In silico. The Cancer research works featured in it incorporate elements from Apoptosis and Cancer therapy.

The most cited articles from the last journal are:

• De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence. (26 citations)
• Melatonin synthesis in and uptake by mitochondria: implications for diseased cells with dysfunctional mitochondria. (8 citations)
• 10 years into the resurgence of covalent drugs (7 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Future Medicinal Chemistry (based on the number of publications) are:

• Jürgen Bajorath (22 papers) published 2 papers at the last edition, 1 more than at the previous edition,
• Kamal Dua (13 papers) published 4 papers at the last edition, 3 less than at the previous edition,
• Riham F. George (12 papers) absent at the last edition,
• Dinesh Kumar Chellappan (11 papers) published 4 papers at the last edition, 2 less than at the previous edition,
• John Spencer (11 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Future Medicinal Chemistry (based on the number of publications) are:

• China Pharmaceutical University (37 papers) published 3 papers at the last edition, 4 less than at the previous edition,
• Cairo University (30 papers) published 3 papers at the last edition, 1 less than at the previous edition,
• University of São Paulo (30 papers) published 6 papers at the last edition, 4 more than at the previous edition,
• Spanish National Research Council (27 papers) absent at the last edition,
• University of Bonn (23 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 9.46% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 11.94% were posted by at least one author from the top 10 institutions publishing in the journal. Another 5.22% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 15.67% of all publications and 67.16% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.